• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    On October 20, Akumin Inc. Reaches Agreement With Stonepeak To Become A Private Company; Existing Stonepeak Note, Totaling ~$470M, Being Cancelled And Converted Into Shares Of The Co, Also Will Invest $130M In New Money To Co As Capital Contribution

    10/23/23 10:43:51 AM ET
    $AKU
    Medical Specialities
    Health Care
    Get the next $AKU alert in real time by email

    https://akumin.com/investor-relations/press-releases/akumin-inc-reaches-agreement-with-stonepeak-to-become-a-private-company/

    Financial restructuring to fortify balance sheet and provide liquidity runway for next stage of growth

    Approvals received from key stakeholders across capital structure; transaction will be implemented through prepackaged court-supervised process; Expected to obtain court approval within the next 45 days

    Business will continue to operate as usual without interruption; trade creditors, employees, and other partners expected to continue to be paid in ordinary course
     

    PLANTATION, FLORIDA, October 20, 2023 — Akumin Inc. ("Akumin" or the "Company") (NASDAQ:AKU, TSX:AKU) announced today that it has reached an agreement with Stonepeak, a leading alternative investment firm specializing in infrastructure and real assets, and the Company's stakeholders on the terms of a financial restructuring that will substantially improve the Company's balance sheet and provide ample liquidity to position Akumin for future success. The contemplated transaction will result in Akumin no longer being publicly listed.

    To effect the transaction in a timely and efficient manner, the Company and certain of its subsidiaries will commence prepackaged chapter 11 cases in the Southern District of Texas. The Company expects to obtain court approval of the transaction within the next 45 days and complete the transaction after receiving certain regulatory approvals. Throughout the process, Akumin's operations are expected to continue as normal. The Company expects to continue to pay trade creditors, employees, and other partners in the ordinary course of business.

    "Today's announcement marks the successful culmination of a thorough strategic review process to ensure we have the right capital structure in place to support our long-term success. As a result of this transaction, Akumin will move forward as a private company with increased financial flexibility and a strengthened balance sheet, better positioned to execute on our strategic plan to become the outpatient partner of choice for hospitals and health systems," said Riadh Zine, Chairman and Chief Executive Officer of Akumin. "We are pleased to enter this agreement with Stonepeak, which we believe will enable us to maximize the value of our business and create the best path forward for all of our stakeholders."

    He continued, "The overwhelming support of our financial partners for this transaction is a testament to the strength of the foundation we have built and their confidence in our future. Akumin has significant scale, extensive and long-standing relationships with hospitals and health systems, a unique service offering, technological expertise in autonomous workflow for healthcare service delivery and a deep bench of talent. We thank our customers, partners, vendors and team members for their continued support of Akumin in its commitment to enhancing patient experiences and outcomes."

    "Stonepeak is committed to working closely with Akumin as it moves through this process," said James Wyper, Senior Managing Director at Stonepeak. "The critical nature of the services Akumin provides to health systems, hospitals, physician groups, and patients all across the country gives us confidence in the inherent value of the business, and we believe that this path forward will fortify the Company's balance sheet as it looks towards its next phase of growth."

    Transaction Details

    The contemplated transaction will result in the existing Stonepeak Note, totaling approximately $470 million, being cancelled and converted into Common Shares of the Company. In addition, Stonepeak will invest $130 million in new money into the Company as a capital contribution.

    To facilitate the transaction, the Company and Stonepeak have executed a Restructuring Support Agreement with over one-third of the Company's common equity, a supermajority of the Company's bondholders, and all of the Company's revolving lenders.  The Restructuring Support Agreement provides that, other than those notes which are exchanged for cash via the reverse Dutch election opportunity described below, the Company's senior secured notes due 2025 will be exchanged for new senior secured notes with a maturity of August 1, 2027 and an increased interest rate, among other changes in terms.  Additionally, the Company's senior secured notes due 2028 will be exchanged for new senior secured notes with the same maturity date but an increased interest rate, among other changes in terms.

    As part of the transaction, Akumin's existing common stockholders will receive a total of $25 million in cash as well as certain contingent value rights ("CVRs") for their shares.

    The transaction will be implemented through a court-supervised process and as such, the Company and certain of its subsidiaries will commence prepackaged chapter 11 cases in the Southern District of Texas. In the event Stonepeak provides debtor-in-possession (DIP) financing or any other new money contributions at or prior to the closing of the transaction, such DIP facilities and new money will convert to equity at closing and reduce the $130 million investment amount on a dollar-for-dollar basis. Stonepeak will also make $60 million of the proceeds from its investment available for a reverse Dutch election opportunity for the Company's notes due 2025 and the notes due 2028.

    Additional details regarding the transaction, including more information about the CVRs, are included in a Form 8-K that is being filed with the SEC concurrently with this release.

    Get the next $AKU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKU

    DatePrice TargetRatingAnalyst
    11/14/2022$3.50 → $3.00Buy → Speculative Buy
    Canaccord Genuity
    More analyst ratings

    $AKU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Akumin Announces Changes to Leadership Team

    Krishna Kumar, Current President & Chief Operating Officer, Appointed Chief Executive Officer Chandra Westergaard Named General Counsel PLANTATION, Fla., Feb. 8, 2024 /CNW/ - Akumin Inc. ("Akumin" or the "Company") announced today that Krishna Kumar, who has served as President and Chief Operating Officer at the Company, has been appointed Chief Executive Officer, effective immediately. He succeeds Riadh Zine, Akumin's Founder, who is stepping down as Chairman and Chief Executive Officer. Akumin also announced that Chandra Westergaard has been named General Counsel and will oversee the Company's legal and compliance functions. "On behalf of Akumin, I would like to thank Riadh for his dedica

    2/8/24 5:00:00 PM ET
    $AKU
    Medical Specialities
    Health Care

    Akumin Inc. Completes Deleveraging Transaction, Becomes a Private Company Wholly-Owned by Stonepeak

    Akumin well-positioned to continue providing top-quality radiology and oncology services to patients, health systems, hospitals, and physician groups across the U.S. PLANTATION, Fla., Feb. 6, 2024 /CNW/ - Akumin Inc. ("Akumin" or the "Company") today announced that it has completed its deleveraging transaction, becoming a private company wholly-owned by Stonepeak, a leading alternative investment firm specializing in infrastructure and real assets. The deleveraging and recapitalization transaction was implemented through a voluntary, court-supervised financial restructuring process, which is now complete. "We are pleased to have concluded this process and are excited to enter our next chapt

    2/6/24 6:26:00 PM ET
    $AKU
    Medical Specialities
    Health Care

    Akumin Inc. Provides Update on its Restructuring Transaction

    /NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES/  PLANTATION, Fla., Jan. 31, 2024 /CNW/ - Akumin Inc. (together with its subsidiaries, "we", "us", "our," "Akumin" or the "Company") (TSX:AKU) (OTC Pink Open Market: AKUMQ) announced today that its previously announced restructuring transaction involving Stonepeak as well as its bondholders, lenders, shareholders and other stakeholders under a prepackaged chapter 11 plan of reorganization (the "Prepackaged Plan") is expected to become effective on or around February 6, 2024 (the "Effective Date"), subject to satisfaction of all of the remaining conditions to the closing of the restructuring transaction. On

    1/31/24 10:26:00 PM ET
    $AKU
    Medical Specialities
    Health Care

    $AKU
    SEC Filings

    View All

    SEC Form EFFECT filed by Akumin Inc.

    EFFECT - AKUMIN INC. (0001776197) (Filer)

    2/13/24 12:15:09 AM ET
    $AKU
    Medical Specialities
    Health Care

    SEC Form 15-12G filed by Akumin Inc.

    15-12G - AKUMIN INC. (0001776197) (Filer)

    2/7/24 6:11:57 AM ET
    $AKU
    Medical Specialities
    Health Care

    SEC Form S-8 POS filed by Akumin Inc.

    S-8 POS - AKUMIN INC. (0001776197) (Filer)

    2/7/24 6:09:57 AM ET
    $AKU
    Medical Specialities
    Health Care

    $AKU
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Akumin downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Akumin from Buy to Speculative Buy and set a new price target of $3.00 from $3.50 previously

    11/14/22 8:59:34 AM ET
    $AKU
    Medical Specialities
    Health Care

    $AKU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Foursixthree Capital Lp claimed ownership of 10,556,851 shares (SEC Form 3)

    3 - AKUMIN INC. (0001776197) (Issuer)

    2/5/24 4:50:02 PM ET
    $AKU
    Medical Specialities
    Health Care

    SEC Form 3 filed by new insider Bienias Ronald J.

    3 - AKUMIN INC. (0001776197) (Issuer)

    10/26/23 10:40:46 AM ET
    $AKU
    Medical Specialities
    Health Care

    SEC Form 4 filed by Kumar Krishna

    4 - AKUMIN INC. (0001776197) (Issuer)

    7/18/23 1:31:57 PM ET
    $AKU
    Medical Specialities
    Health Care

    $AKU
    Financials

    Live finance-specific insights

    View All

    Akumin Inc. Provides Update on its Restructuring Transaction

    /NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. WIRE SERVICES/  PLANTATION, Fla., Jan. 31, 2024 /CNW/ - Akumin Inc. (together with its subsidiaries, "we", "us", "our," "Akumin" or the "Company") (TSX:AKU) (OTC Pink Open Market: AKUMQ) announced today that its previously announced restructuring transaction involving Stonepeak as well as its bondholders, lenders, shareholders and other stakeholders under a prepackaged chapter 11 plan of reorganization (the "Prepackaged Plan") is expected to become effective on or around February 6, 2024 (the "Effective Date"), subject to satisfaction of all of the remaining conditions to the closing of the restructuring transaction. On

    1/31/24 10:26:00 PM ET
    $AKU
    Medical Specialities
    Health Care

    Akumin Announces Second Quarter 2023 Results, Revised FY23 Financial Outlook and Establishment of Special Committee

    PLANTATION, Fla., Aug. 9, 2023 /PRNewswire/ - Akumin Inc. (NASDAQ:AKU) (TSX:AKU) ("Akumin" or the "Company"), a national partner of choice for U.S. hospitals, health systems and physician groups, with comprehensive solutions addressing outsourced radiology and oncology service-line needs, announced today its financial results for the quarter ended June 30, 2023. Second Quarter 2023 Highlights Akumin delivered second quarter same-store volume performance on a consolidated basis as follows:+3.1% for MRI+16.5% for PET/CT+3.4% for Oncology Patient StartsThe Company reported revenue totaling $184.8 million for the second quarter, a $7.3 million or 4% decrease over the second quarter of last year.

    8/9/23 5:23:00 PM ET
    $AKU
    Medical Specialities
    Health Care

    Akumin to Host Second Quarter 2023 Financial Results Call on August 10, 2023

    PLANTATION, Fla., Aug. 8, 2023 /PRNewswire/ - Akumin Inc. (TSX:AKU) ("Akumin" or the "Company") will host a conference call at 8:30 a.m. Eastern Time, Thursday, August 10, 2023, to discuss its second quarter 2023 financial results.  The financial results are expected to be available on Wednesday, August 9, 2023. To access the conference call, participants may join by using an appropriate dial-in number available through https://akum.in/Q2-2023-Results-Dial-In-Numbers or via webcast at https://akum.in/Q2-2023-Results-Webcast. A related presentation will be available from Akumin's website (www.akumin.com). Participants are asked to connect at least 10 minutes prior to the beginning of the call

    8/8/23 5:23:00 PM ET
    $AKU
    Medical Specialities
    Health Care

    $AKU
    Leadership Updates

    Live Leadership Updates

    View All

    AKUMIN ANNOUNCES LEADERSHIP TRANSITION

    PLANTATION, Fla., Dec. 29, 2023 /CNW/ - Akumin Inc. (together with its subsidiaries, "we", "us", "our," "Akumin" or the "Company") (TSX:AKU) (OTC Pink Open Market: AKUMQ) announced today that its Board of Directors has appointed Ronald J. Bienias, Akumin's Chief Restructuring Officer and Partner and Managing Director of AlixPartners, LLP, as Interim Chief Financial Officer, effective today. He will also maintain his current role as Chief Restructuring Officer. Ronald's appointment follows the resignation of David Kretschmer, as Akumin's Chief Financial Officer effective today. Ronald has more than 20 years of experience serving in interim leadership roles or as an advisor at both large and

    12/29/23 7:52:00 PM ET
    $AKU
    Medical Specialities
    Health Care

    Akumin Announces Change of Auditor

    PLANTATION, Fla., Aug. 9, 2023 /PRNewswire/ - Akumin Inc. ("Akumin" or the "Company") (NASDAQ:AKU) (TSX:AKU) announced today that it has changed its auditor from Ernst & Young LLP ("EY") to Deloitte & Touche LLP ("Deloitte"). Effective as of August 9, 2023, the audit committee (the "Audit Committee") of the board of directors (the "Board") of the Company dismissed EY as the Company's independent registered public accounting firm. EY audited the Company's financial statements for each of the past two fiscal years ended December 31, 2022 and 2021, and EY's reports did not contain any adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope, or

    8/9/23 5:31:00 PM ET
    $AKU
    Medical Specialities
    Health Care

    Akumin appoints President and Chief Operating Officer

    PLANTATION, Fla., June 12, 2023 /CNW/ - Akumin Inc. ("Akumin" or the "Company") (NASDAQ:AKU) (TSX:AKU) today announced the appointment of Krishna Kumar as President and Chief Operating Officer of the Company, effective as of June 16, 2023. Krishna has valuable experience and exceptional insight into the radiology space, having served as Senior Vice President & Business Leader - Precision Diagnosis at Philips North America, where he built a top performing team and business, over the last four years. Prior to this role, he led global businesses in Pathology, Oncology and Neuro at Philips based in Amsterdam, Netherlands from 2015-2019 and prior thereto was the CEO of Philips India. Before joini

    6/12/23 6:59:57 AM ET
    $AKU
    Medical Specialities
    Health Care

    $AKU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Akumin Inc. (Amendment)

    SC 13G/A - AKUMIN INC. (0001776197) (Subject)

    2/12/24 4:37:41 PM ET
    $AKU
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Akumin Inc.

    SC 13G - AKUMIN INC. (0001776197) (Subject)

    2/12/24 4:31:27 PM ET
    $AKU
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Akumin Inc. (Amendment)

    SC 13G/A - AKUMIN INC. (0001776197) (Subject)

    2/7/24 10:43:55 AM ET
    $AKU
    Medical Specialities
    Health Care